Anti-CD34 Antibody Picoband®

Western blot analysis of CD34 using anti-CD34 antibody (PA1334).
Electrophoresis was performed on a 5-20% SDS-PAGE gel at 70V (Stacking gel) / 90V (Resolving gel) for 2-3 hours. The sample well of each lane was loaded with 30 ug of sample under reducing conditions.
Lane 1: human placenta tissue lysates,
Lane 2: rat brain tissue lysates,
Lane 3: mouse brain tissue lysates.
After electrophoresis, proteins were transferred to a nitrocellulose membrane at 150 mA for 50-90 minutes. Blocked the membrane with 5% non-fat milk/TBS for 1.5 hour at RT. The membrane was incubated with rabbit anti-CD34 antigen affinity purified polyclonal antibody (Catalog # PA1334) at 0.5 μg/mL overnight at 4°C, then washed with TBS-0.1%Tween 3 times with 5 minutes each and probed with a goat anti-rabbit IgG-HRP secondary antibody at a dilution of 1:5000 for 1.5 hour at RT. The signal is developed using an Enhanced Chemiluminescent detection (ECL) kit (Catalog # EK1002) with Tanon 5200 system. A specific band was detected for CD34 at approximately 105 kDa. The expected band size for CD34 is at 41 kDa.

IHC analysis of CD34 using anti-CD34 antibody (PA1334).
CD34 was detected in a paraffin-embedded section of Rat Kidney tissue. Heat mediated antigen retrieval was performed in EDTA buffer (pH 8.0, epitope retrieval solution). The tissue section was blocked with 10% goat serum. The tissue section was then incubated with 2 μg/ml rabbit anti-CD34 Antibody (PA1334) overnight at 4°C. Peroxidase Conjugated Goat Anti-rabbit IgG was used as secondary antibody and incubated for 30 minutes at 37°C. The tissue section was developed using HRP Conjugated Rabbit IgG Super Vision Assay Kit (Catalog # SV0002) with DAB as the chromogen.

IHC analysis of CD34 using anti-CD34 antibody (PA1334).
CD34 was detected in a paraffin-embedded section of Human Lung Cancer tissue. Heat mediated antigen retrieval was performed in EDTA buffer (pH 8.0, epitope retrieval solution). The tissue section was blocked with 10% goat serum. The tissue section was then incubated with 2 μg/ml rabbit anti-CD34 Antibody (PA1334) overnight at 4°C. Peroxidase Conjugated Goat Anti-rabbit IgG was used as secondary antibody and incubated for 30 minutes at 37°C. The tissue section was developed using HRP Conjugated Rabbit IgG Super Vision Assay Kit (Catalog # SV0002) with DAB as the chromogen.

IHC analysis of CD34 using anti-CD34 antibody (PA1334).
CD34 was detected in a paraffin-embedded section of human liver cancer tissue. Heat mediated antigen retrieval was performed in EDTA buffer (pH 8.0, epitope retrieval solution). The tissue section was blocked with 10% goat serum. The tissue section was then incubated with 2 μg/ml rabbit anti-CD34 Antibody (PA1334) overnight at 4°C. Peroxidase Conjugated Goat Anti-rabbit IgG was used as secondary antibody and incubated for 30 minutes at 37°C. The tissue section was developed using HRP Conjugated Rabbit IgG Super Vision Assay Kit (Catalog # SV0002) with DAB as the chromogen.

IHC analysis of CD34 using anti-CD34 antibody (PA1334).
CD34 was detected in a paraffin-embedded section of human placenta tissue. Heat mediated antigen retrieval was performed in EDTA buffer (pH 8.0, epitope retrieval solution). The tissue section was blocked with 10% goat serum. The tissue section was then incubated with 2 μg/ml rabbit anti-CD34 Antibody (PA1334) overnight at 4°C. Peroxidase Conjugated Goat Anti-rabbit IgG was used as secondary antibody and incubated for 30 minutes at 37°C. The tissue section was developed using HRP Conjugated Rabbit IgG Super Vision Assay Kit (Catalog # SV0002) with DAB as the chromogen.

IHC analysis of CD34 using anti-CD34 antibody (PA1334).
CD34 was detected in a paraffin-embedded section of mouse kidney tissue. Heat mediated antigen retrieval was performed in EDTA buffer (pH 8.0, epitope retrieval solution). The tissue section was blocked with 10% goat serum. The tissue section was then incubated with 2 μg/ml rabbit anti-CD34 Antibody (PA1334) overnight at 4°C. Peroxidase Conjugated Goat Anti-rabbit IgG was used as secondary antibody and incubated for 30 minutes at 37°C. The tissue section was developed using HRP Conjugated Rabbit IgG Super Vision Assay Kit (Catalog # SV0002) with DAB as the chromogen.

IHC analysis of CD34 using anti-CD34 antibody (PA1334).
CD34 was detected in paraffin-embedded section of rat kidney tissues. Heat mediated antigen retrieval was performed in citrate buffer (pH6, epitope retrieval solution) for 20 mins. The tissue section was blocked with 10% goat serum. The tissue section was then incubated with 1μg/ml rabbit anti-CD34 Antibody (PA1334) overnight at 4°C. Biotinylated goat anti-rabbit IgG was used as secondary antibody and incubated for 30 minutes at 37°C. The tissue section was developed using Strepavidin-Biotin-Complex (SABC)(Catalog # SA1022) with DAB as the chromogen.

IHC analysis of CD34 using anti-CD34 antibody (PA1334).
CD34 was detected in a frozen section of Rat Placenta tissue. The tissue section was blocked with 10% goat serum. The tissue section was then incubated with 1 μg/ml rabbit anti-CD34 Antibody (PA1334) overnight at 4°C. Biotinylated goat anti-rabbit IgG was used as secondary antibody and incubated for 30 minutes at 37°C. The tissue section was developed using HRP Conjugated Rabbit IgG Super Vision Assay Kit (Catalog # SV0002) with DAB as the chromogen.

IHC analysis of CD34 using anti-CD34 antibody (PA1334).
CD34 was detected in a frozen section of Rat Kidney tissue. The tissue section was blocked with 10% goat serum. The tissue section was then incubated with 1 μg/ml rabbit anti-CD34 Antibody (PA1334) overnight at 4°C. Biotinylated goat anti-rabbit IgG was used as secondary antibody and incubated for 30 minutes at 37°C. The tissue section was developed using HRP Conjugated Rabbit IgG Super Vision Assay Kit (Catalog # SV0002) with DAB as the chromogen.

Flow Cytometry analysis of HEL cells using anti-CD34 antibody (PA1334).
Overlay histogram showing HEL cells stained with PA1334 (Blue line). The cells were fixed with 4% paraformaldehyde and blocked with 10% normal goat serum. And then incubated with rabbit anti-CD34 Antibody (PA1334, 1 μg/1x10⁶ cells) for 30 min at 20°C. DyLight®488 conjugated goat anti-rabbit IgG (BA1127, 5-10 μg/1x10⁶ cells) was used as secondary antibody for 30 minutes at 20°C. Isotype control antibody (Green line) was rabbit IgG (1 μg/1x10⁶) used under the same conditions. Unlabelled sample without incubation with primary antibody and secondary antibody (Red line) was used as a blank control.

DPPA inhibits MDA-MB-231 subcutaneous tumor growth in vivo . MDA-MB-231 cells were injected into the mammary fat pads of athymic nude mice, and 7 days later, DPPA (3 mg/kg body weight) or DMSO was injected once every two days for two weeks. DPPA significantly suppressed tumor volume (A) and tumor weight (B). DPPA inhibited tumor cell proliferation and angiogenesis, which were measured using Ki67 (C) and CD34 (D) staining, respectively, in an IHC assay. N = 8, * P < 0.05, ** P < 0.01 and *** P < 0.001. Scale bars: 50 μm.
Index in PubMed under a CC BY license. PMID: 28529455

Primary culture and characterization of rat EPCs. (A) Rat BM-MNCs from bone marrow after 7 days in culture (100×). (B) Rat BM-MNCs after 14 days of culture (100×). (C) CD31, CD34, CD133 and VEGFR-2 expression was detected using immunofluorescence (200×). (D) EPCs differentiation potential into adipocytes was demonstrated using oil red-O staining (100×). (E) EPCs differentiation potential into smooth muscle cells was demonstrated using immunofluorescence staining (200×). (F) The expression of eNOS in EPCs was identified using Western blotting analyses. Human umbilical vein endothelial cells was used as positive control. Cavernous smooth muscle cells was used as negative control. (G) Tube formation assay was examined microscopically (100×).
Index in PubMed under a CC BY license. PMID: 27283992

DPPA inhibits 4T1 subcutaneous tumor growth in vivo . (A) The structure of DPPA. 4T1 cells were injected into the mammary fat pads of BALB/c mice, and 9 days later, DPPA (3 mg/kg body weight) or DMSO was injected once every two days for two weeks. DPPA significantly suppressed tumor volume (B) and tumor weight (C) in a mouse 4T1 subcutaneous tumor model. DPPA inhibited tumor cell proliferation and angiogenesis, which were measured by Ki67 (D) and CD34 (E) staining, respectively, using an IHC assay. N = 8, * P < 0.05, *** P < 0.001. Scale bars: 50 μm.
Index in PubMed under a CC BY license. PMID: 28529455

Effects of three therapies on angiogenesis, cell proliferation, and apoptosis of SOI tumor. Representative pictures of blood vessels and lymphatic stained with CD34, D2-40, proliferative cells stained with Ki-67, Bcl-2, Bcl-6, and apoptotic cells stained with Tunel antibodies in Control, DOX, PDOX group. Original magnification 40×, treatment with PDOX resulted in decreased Ki-67-positive cells.
Index in PubMed under a CC BY license. PMID: 29416744

A – D CD34 immunoreactivity in endometriotic ovary 28 days p.t. of control EMS ( A ), DCI ( B ), DG + DCI ( C ) and DG ( D )-treated mice by LM. mag. 20X; bar: 50 µm; E – H ) PCNA immunoreactivity in endometriotic ovary 28 days p.t. of control EMS ( E ), DCI ( F ), DG + DCI ( G ) and DG ( H )-treated mice by LM. mag. 20X; bar: 50 µm. I – L IL-1β immunoreactivity in endometriotic ovary 28 days p.t. of control EMS ( I ), DCI ( J ), DG + DCI ( K ) and DG-treated ( L )-treated mice by LM. mag. 20X; bar: 50 µm. M – P E-Cadherin immunoreactivity in endometriotic ovary 28 days p.t. of control EMS ( M ), DCI ( N ), DG + DCI ( O ) and DG ( P )-treated mice by LM. mag. 20X; bar: 50 µm
Index in PubMed under a CC BY license. PMID: 40211112

H&E ( A – B ) and Trichrome AZAN ( C – D ) stainings of representative endometriotic lesions in DCI-treated mice 28 days p.t. by LM. A , D mag. 10X; bar: 100 µm. B , E mag. 20X; bar: 50 µm. C , F mag. 40X; bar: 20 µm ( E – F ) and Trichrome AZAN ( G , H ) stainings of representative endometriotic lesions in DG + DCI-treated mice 28 days p.t. by LM. E , G mag. 20X; bar: 50 µm. F , H mag. 40X; bar: 20 µm. H&E ( I – K ) and Trichrome AZAN ( J – L ) stainings of representative endometriotic lesions in DG-treated mice 28 days p.t. by LM. I , J mag. 20X; bar: 50 µm. K , L mag. 40X; bar: 20 µm. M – T PCNA immunoreactivity in endometriotic lesions 28 days p.t. of control EMS ( M , N ), DCI-treated ( O , P ), DG + DCI ( Q , R ) and DG-treated ( S , T )-treated mice by LM. M , O , Q , S LM, mag. 20X; bar: 50 µm. N , P , R , T mag. 40X; bar: 20 µm. U – AB CD34 immunoreactivity in endometriotic lesions 28 days p.t. of control EMS ( U , V ), DCI-treated ( W , X ), DG + DCI ( Y , Z ) and DG-treated ( AA , AB )-treated mice by LM. U , W , Y , AA mag. 20X; bar: 50 µm. V , X , Z , AB mag. 40X; bar: 20 µm
Index in PubMed under a CC BY license. PMID: 40211112

Andro inhibits cell proliferation and angiogenesis and induces cell apoptosis in insulinoma. (A) Andro inhibited the tumor cell proliferation, which was measured using the BrdU cell proliferation assay, in RIP1-Tag2 mice. (B) Cell apoptosis was increased, which was examined through TUNEL staining, in Andro treated tumor tissue compared with control groups. (C) and (D) Andro suppressed the tumor angiogenesis, which was measured using the immunohistochemical staining of CD34 and VEGF, in RIP1-Tag2 mice. n=6, * P < 0.05, ** P < 0.01. Bar, 20 μm.
Index in PubMed under a CC BY license. PMID: 24719558